USPTO Allows Claims in Alnylam RNAi Patent Application | GenomeWeb

Alnylam Pharmaceuticals said this week that the US Patent and Trademark Office has allowed a patent application covering compositions and methods for siRNAs.

The application, No. 20070275465, is entitled, "Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism." According to Alnylam, claims in the application include a dsRNA of any length having effectiveness in inhibiting a target gene via RNAi; overhang or blunt-end design features; and a 19 to 28 nucleotide region of the antisense strand that is complementary to a target gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?